February 2026
Altered states of consciousness
What February 2026's 8 new studies found, synthesized from the papers below. All Altered states of consciousness research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Altered states of consciousness, non-ordinary states, altered consciousness, ASC, then ranked by relevance.
Research in February 2026 indicates that ayahuasca and its main psychoactive component DMT show promise for treating mental disorders and modulating fear memories, with evidence from preclinical and observational human studies suggesting enhanced neuroplasticity and reduced default mode network activity. However, the evidence is limited by small sample sizes, a lack of randomized controlled trials, and potential drug-drug interactions with SSRIs. The findings are consistent in pointing toward therapeutic potential but remain preliminary.
Confidence in the evidence
Low-Moderate- Evidence includes one review summarizing mainly observational human studies and preclinical work, with no large-scale RCTs.
- One non-human primate study with small sample size suggests prophylactic effects on stress-induced cortical atrophy.
- One rodent study shows ayahuasca enhances fear extinction via BDNF-dependent mechanisms, but generalizability to humans is limited.
- A modeling study indicates clinically relevant interactions between ayahuasca and SSRIs, highlighting safety concerns.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind 2026 | review | Supports | This review highlights ayahuasca and DMT's therapeutic potential for treatment-resistant psychiatric disorders, noting limited clinical trials but optimistic outlook. | |
| Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies 2026 | review | Supports | This review summarizes preclinical and clinical evidence showing ayahuasca's benefits for depression, anxiety, PTSD, and substance use disorders, but notes evidence is mainly observational and randomized trials are needed. | |
| Preliminary analysis of ayahuasca-induced anatomical alterations in the somatosensory cortex of juvenile non-human primates (Callithrix jacchus) subjected to chronic stress 2026 | preclinical | Supports | Ayahuasca treatment prevented stress-induced reduction in neuronal volume in the somatosensory cortex, suggesting a prophylactic effect against cortical atrophy. | |
| Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling 2026 | modeling study | Opposes | This modeling study predicts clinically relevant drug-drug interactions between ayahuasca and SSRIs, with increased DMT exposure potentially intensifying serotonergic effects. | |
| Shamanic tradition and altered states of consciousness in Turkic culture 2026 | qualitative | Unclear | This study examines altered states of consciousness in Turkic shamanic tradition, describing ASC as a normative tool for diagnosis and social regulation, but does not directly address therapeutic effects. | |
| RESENHA CRÍTICA DA OBRA VISÕES MULTIDISCIPLINARES DA AYAHUASCA 2026 | review | Supports | This critical review of a multidisciplinary book on ayahuasca highlights its therapeutic potential in mental health and drug use disorders, while noting the need for deeper exploration of indigenous perspectives. | |
| Representing mental images and immaterial processes in VR. A new materialist reading of Manic VR and Ayahuasca – Kosmik Journey 2026 | theoretical | Unclear | This article analyzes VR representations of mystical-type experiences associated with psychedelics, focusing on atmospheric mechanisms, but does not provide empirical data on therapeutic outcomes. | |
| Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats. 2026 | preclinical | Supports | Ayahuasca enhanced fear extinction and reduced fear generalization in rats, effects dependent on BDNF-TrkB signaling in the infralimbic cortex, with sex-specific differences. |
This review highlights ayahuasca and DMT's therapeutic potential for treatment-resistant psychiatric disorders, noting limited clinical trials but optimistic outlook.
review
This review summarizes preclinical and clinical evidence showing ayahuasca's benefits for depression, anxiety, PTSD, and substance use disorders, but notes evidence is mainly observational and randomized trials are needed.
review
Ayahuasca treatment prevented stress-induced reduction in neuronal volume in the somatosensory cortex, suggesting a prophylactic effect against cortical atrophy.
preclinical
This modeling study predicts clinically relevant drug-drug interactions between ayahuasca and SSRIs, with increased DMT exposure potentially intensifying serotonergic effects.
modeling study
This study examines altered states of consciousness in Turkic shamanic tradition, describing ASC as a normative tool for diagnosis and social regulation, but does not directly address therapeutic effects.
qualitative
This critical review of a multidisciplinary book on ayahuasca highlights its therapeutic potential in mental health and drug use disorders, while noting the need for deeper exploration of indigenous perspectives.
review
This article analyzes VR representations of mystical-type experiences associated with psychedelics, focusing on atmospheric mechanisms, but does not provide empirical data on therapeutic outcomes.
theoretical
Ayahuasca enhanced fear extinction and reduced fear generalization in rats, effects dependent on BDNF-TrkB signaling in the infralimbic cortex, with sex-specific differences.
preclinical
Points of agreement
- Multiple reviews and preclinical studies agree that ayahuasca/DMT shows therapeutic potential for mental health disorders, particularly through mechanisms like enhanced neuroplasticity and modulation of fear memories.
- Preclinical evidence consistently indicates ayahuasca can prevent stress-induced neural changes and facilitate fear extinction.
Conflicts
- The modeling study predicting drug-drug interactions with SSRIs raises safety concerns that are not addressed in the therapeutic reviews.
- The qualitative and theoretical studies on shamanic traditions and VR representations do not directly align with the clinical/preclinical focus of other studies.
Gaps
- No large-scale randomized controlled trials in humans are reported; evidence is primarily observational or preclinical.
- Durability of therapeutic effects and long-term safety are not addressed.
- Sex-specific effects are noted in one rodent study but not explored in human studies.
- Potential interactions with SSRIs are modeled but not tested in controlled human studies.